IE 11 is not supported. For an optimal experience visit our site on another browser.

Integra LifeSciences to Present at the Canaccord Genuity Musculoskeletal Conference

PLAINSBORO, N.J., Feb. 7, 2011 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that Mr. Brian Larkin, President, Global Spine, and Head of Strategic Development of Integra, will present at the Canaccord Genuity Musculoskeletal Conference. The presentation will take place on Tuesday, February 15 at 2:00pm PT at the Westin San Diego in San Diego, CA. A live webcast will be accessible through a link provided on the Investor Relations homepage of Integra's website, www.integralife.com. 
/ Source: GlobeNewswire

PLAINSBORO, N.J., Feb. 7, 2011 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that Mr. Brian Larkin, President, Global Spine, and Head of Strategic Development of Integra, will present at the Canaccord Genuity Musculoskeletal Conference. The presentation will take place on Tuesday, February 15 at 2:00pm PT at the Westin San Diego in San Diego, CA. A live webcast will be accessible through a link provided on the Investor Relations homepage of Integra's website, . 

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit .

Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

IART-G

CONTACT: Integra LifeSciences Holdings Corporation John B. Henneman, III Executive Vice President Finance and Administration and Chief Financial Officer (609) 275-0500 jack.henneman@integralife.com Investor Relations: Angela Steinway (609) 936-2268 angela.steinway@integralife.com